HALO Relative Valuation
HALO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HALO is overvalued; if below, it's undervalued.
Historical Valuation
Halozyme Therapeutics Inc (HALO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.40 is considered Undervalued compared with the five-year average of 15.06. The fair price of Halozyme Therapeutics Inc (HALO) is between 95.19 to 152.27 according to relative valuation methord. Compared to the current price of 70.50 USD , Halozyme Therapeutics Inc is Undervalued By 25.94%.
Relative Value
Fair Zone
95.19-152.27
Current Price：70.50
25.94%
Undervalued
9.47
PE
1Y
3Y
5Y
Trailing
Forward
7.60
EV/EBITDA
Halozyme Therapeutics Inc. (HALO) has a current EV/EBITDA of 7.60. The 5-year average EV/EBITDA is 14.13. The thresholds are as follows: Strongly Undervalued below 5.42, Undervalued between 5.42 and 9.78, Fairly Valued between 18.48 and 9.78, Overvalued between 18.48 and 22.84, and Strongly Overvalued above 22.84. The current Forward EV/EBITDA of 7.60 falls within the Undervalued range.
8.25
EV/EBIT
Halozyme Therapeutics Inc. (HALO) has a current EV/EBIT of 8.25. The 5-year average EV/EBIT is 15.64. The thresholds are as follows: Strongly Undervalued below 6.46, Undervalued between 6.46 and 11.05, Fairly Valued between 20.23 and 11.05, Overvalued between 20.23 and 24.82, and Strongly Overvalued above 24.82. The current Forward EV/EBIT of 8.25 falls within the Undervalued range.
70.63
PS
Halozyme Therapeutics Inc. (HALO) has a current PS of 70.63. The 5-year average PS is 8.35. The thresholds are as follows: Strongly Undervalued below -4.46, Undervalued between -4.46 and 1.94, Fairly Valued between 14.76 and 1.94, Overvalued between 14.76 and 21.16, and Strongly Overvalued above 21.16. The current Forward PS of 70.63 falls within the Strongly Overvalued range.
8.21
P/OCF
Halozyme Therapeutics Inc. (HALO) has a current P/OCF of 8.21. The 5-year average P/OCF is 16.06. The thresholds are as follows: Strongly Undervalued below 3.83, Undervalued between 3.83 and 9.95, Fairly Valued between 22.18 and 9.95, Overvalued between 22.18 and 28.30, and Strongly Overvalued above 28.30. The current Forward P/OCF of 8.21 falls within the Undervalued range.
8.26
P/FCF
Halozyme Therapeutics Inc. (HALO) has a current P/FCF of 8.26. The 5-year average P/FCF is 15.71. The thresholds are as follows: Strongly Undervalued below 5.12, Undervalued between 5.12 and 10.41, Fairly Valued between 21.00 and 10.41, Overvalued between 21.00 and 26.29, and Strongly Overvalued above 26.29. The current Forward P/FCF of 8.26 falls within the Undervalued range.
Halozyme Therapeutics Inc (HALO) has a current Price-to-Book (P/B) ratio of 16.36. Compared to its 3-year average P/B ratio of 33.19 , the current P/B ratio is approximately -50.72% higher. Relative to its 5-year average P/B ratio of 36.51, the current P/B ratio is about -55.20% higher. Halozyme Therapeutics Inc (HALO) has a Forward Free Cash Flow (FCF) yield of approximately 0.07%. Compared to its 3-year average FCF yield of 6.15%, the current FCF yield is approximately -98.81% lower. Relative to its 5-year average FCF yield of 5.06% , the current FCF yield is about -98.56% lower.
16.47
P/B
Median3y
33.19
Median5y
36.51
0.07
FCF Yield
Median3y
6.15
Median5y
5.06
Competitors Valuation Multiple
The average P/S ratio for HALO's competitors is 69.61, providing a benchmark for relative valuation. Halozyme Therapeutics Inc Corp (HALO) exhibits a P/S ratio of 70.63, which is 1.47% above the industry average. Given its robust revenue growth of 22.12%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HALO increased by 46.54% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 290.08M to 354.26M.
The secondary factor is the P/E Change, contributed 19.70%to the performance.
Overall, the performance of HALO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Halozyme Therapeutics Inc (HALO) currently overvalued or undervalued?
What is Halozyme Therapeutics Inc (HALO) fair value?
How does HALO's valuation metrics compare to the industry average?
What is the current P/B ratio for Halozyme Therapeutics Inc (HALO) as of Nov 13 2025?
What is the current FCF Yield for Halozyme Therapeutics Inc (HALO) as of Nov 13 2025?
What is the current Forward P/E ratio for Halozyme Therapeutics Inc (HALO) as of Nov 13 2025?